Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
Global health company The Cigna Group (NYSE:CI) will release its fourth quarter 2024 financial results on Thursday, January ...
Adventist HealthCare has identified the next leader of its Fort Washington Medical Center, after Eunmee Shim stepped out of ...
Investing in women’s health can drive innovation, improve health outcomes for women globally, and unlock significant ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...